| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.059 | 0.05 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.05 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.055 | 0.05 |
| mRNA | Vinorelbine | GDSC1000 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.064 | 0.06 |